New study maps hidden cancer spread in stomach surgery
NCT ID NCT06728891
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at where tumor deposits form after gastric cancer surgery. Researchers will examine tissue from 100 patients who had a specific type of stomach removal. The goal is to learn more about how cancer spreads in the abdomen, which may guide future treatments.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better understand where gastric cancer spreads, potentially improving future surgical techniques.
- What could go wrong
- This is an observational study with no treatment being tested, so it won't directly lead to a new therapy. Results may not change current practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2024
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients undergoing proximal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision. At the same time, the patients met the above inclusion and exclusion criteria.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Aged older than 18 years and younger than 85 years 2. Primary gastric adenocarcinoma confirmed by preoperative pathology result 3. cT2-4aN0-3M0 at preoperative evaluation according to the American Joint 8 Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition 4. Patients undergoing proximal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision 5. American Society of Anesthesiologists (ASA) class I, II, or III 6. Written informed consent Exclusion Criteria: 1. Negative preoperative biopsy 2. Too late tumour stage or metastasis (cT4b/M1) 3. BMI\>30 kg/m2 4. previous neoadjuvant chemotherapy or radiotherapy 5. Previous upper abdominal surgery 6. Combined with other malignant diseases 7. Reject operation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gastric adenocarcinoma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Department of Gastrointestinal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One small incision vs several: robotic stomach cancer surgery put to the test
- Can PET scans reveal which stomach cancers will respond to immunotherapy?
- Can a direct hit to tumors make immunotherapy work better?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Can a vaccine stop GI cancers from returning?
- Blood test aims to catch Cancer's return earlier